TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04887298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Annamycin (L-Annamycin)
Description: 2-hour intravenous (IV) infusion of L-Annamycin on Day 1 followed by 20 days off of study drug (i.e., 1 treatment cycle= 21 days)
Study: NCT06346522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin (Gaptin ®) 400mg oral capsule once
Description: After the patient will regain feeding, the patients will take with sips of water Gabapentin (Gaptin ®) 400mg oral capsule once in the first 24 hour after icu admission

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule
Description: After the patient will regain feeding, the patients will take with sips of water Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule once in the first 24 hour after icu admission
Study: NCT05299892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audeo P or Naida P hearing aid
Description: Commercially available hearing aid that has access to speech enhancer feature settings off, moderate and strong
Study: NCT05274438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001+Imatinib mesylate
Description: This study consisted of two phases: the first phase was the dose exploration phase, and the second phase was the extension group. In phase I, 3 patients were enrolled, starting with imatinib monotherapy, 400mg qd, for 2 cycles (6 weeks), followed by imatinib 400mg qd combined with toripalimab 240mg q3w. If DLT was not observed, the original dose was extended to 37 patients in phase ii; If there was 1 DLT in the first stage, the number of patients in the first stage was extended to 6. If there was no DLT, the patients entered the extended stage. If ≥2 DLT cases occurred in the first phase, imatinib was reduced to 300mg QD and toripalimab 240mg q3W, and the 3+3 study was restarted. If DLT≤1 case, enter extended group (imatinib 300mg qd and toripalimab 240mg q3W); The longest cumulative use period of the two drugs was 2 years. When patients develop disease progression or develop intolerable toxicity, treatment is ended and follow-up for survival is entered.
Study: NCT06204315

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Given by RTx
Study: NCT05929586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The combined C-it DU-it intervention: community data use for ANC
Description: Combining data linkage (C-it) with work improvement teams for community data use (DU-it) to improve antenatal clinic uptake. Our short name C-it DU-it (pronounced see-it; do-it) is an acronym intended to convey 'seeing' linked data (C-it) and 'doing' or acting on the data (DU-it)
Study: NCT05900245

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Index of consciousness+Anesthetic（propofol）+Muscle relaxant（Succinylcholine）
Description: EEG monitoring is performed before induction of electrical shock anesthesia（propofol1.5mg/kg+Succinylcholine1mg/kg）, and the timing of electrical stimulation is determined based on the level of consciousness index 1 displayed on the EEG.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Index of consciousness+Anesthetic（propofol）+Muscle relaxant（Succinylcholine）
Description: EEG monitoring is performed before induction of electrical shock anesthesia（propofol1.5mg/kg+Succinylcholine1mg/kg）, and the timing of electrical stimulation is determined based on the level of consciousness index 1 displayed on the EEG.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Index of consciousness+Anesthetic（propofol）+Muscle relaxant（Succinylcholine）
Description: EEG monitoring is performed before induction of electrical shock anesthesia（propofol1.5mg/kg+Succinylcholine1mg/kg）, and the timing of electrical stimulation is determined based on the level of consciousness index 1 displayed on the EEG.
Study: NCT06398314

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Palliative radiotherapy
Description: Hypofractionated radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Palliative radiotherapy
Description: Hypofractionated radiotherapy
Study: NCT05324371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Watchman FLX Device
Description: Left atrial appendage closure using the Watchman FLX device
Study: NCT05947071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose Quadrivalent Inactivated Influenza Vaccine
Description: Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Quadrivalent Inactivated Influenza Vaccine
Description: Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration.
Study: NCT05195138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Diabetes Education
Description: Mindfulness-Based Diabetes Education described in study arm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Self-Management Education (DSME)
Description: Standard DSME described in study arm.
Study: NCT05991232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine
Description: Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
Study: NCT05740904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New defocus spectacle lenses
Description: The children in the new defocus spectacle lens group will wear new defocus spectacle and receive follow-up examinations every half year.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Convenional aspheric single-vision spectacle lenses
Description: The children in the convenional aspheric spectacle lenses group will wear conventional aspheric single-vision spectacle and receive follow-up examinations every half year.
Study: NCT05030298

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Undergo radiosurgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Biopsy
Description: Undergo MRI-guided stereotactic biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Drug

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Undergo TTF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT06157905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Tofacitinib citrate
Description: oral tofacitinib citrate was initiated at 5 mg twice daily after ruling out contraindications
Study: NCT05163847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cam2020 M2SR H3N2 influenza vaccine
Description: Administered intranasally on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cam2020 M2SR H3N2 influenza vaccine
Description: Administered intranasally on Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone HD IIV
Description: Administered intramuscularly on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone HD IIV
Description: Administered intramuscularly on Day 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IN Placebo
Description: Administered intranasally on Day 1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IN Placebo
Description: Administered intranasally on Day 1
Study: NCT05842798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNM002
Description: TNM002, intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNM002
Description: TNM002, intramuscular injection
Study: NCT05163847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IM Placebo
Description: Administered intramuscularly on Day 1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IM Placebo
Description: Administered intramuscularly on Day 1
Study: NCT05842798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNM002
Description: TNM002, intramuscular injection
Study: NCT05570487

Intervention type: DIAGNOSTIC_TEST
Intervention: Since the data were collected retrospectively, there were no interventions
Description: Since the data were collected retrospectively, there were no interventions

Intervention type: DIAGNOSTIC_TEST
Intervention: Since the data were collected retrospectively, there were no interventions
Description: Since the data were collected retrospectively, there were no interventions

Intervention type: DIAGNOSTIC_TEST
Intervention: Since the data were collected retrospectively, there were no interventions
Description: Since the data were collected retrospectively, there were no interventions

Intervention type: DIAGNOSTIC_TEST
Intervention: Since the data were collected retrospectively, there were no interventions
Description: Since the data were collected retrospectively, there were no interventions
Study: NCT03991273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Y-M2M©
Description: The Y-M2M© group will receive classes that will be delivered onsite at a YMCA facility. Movement-to-Music (M2M©) is an instructor-guided exercise program that is coupled with music to enhance strength, cardiorespiratory capacity, range of motion, and balance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Y-M2M©
Description: The Y-M2M© group will receive classes that will be delivered onsite at a YMCA facility. Movement-to-Music (M2M©) is an instructor-guided exercise program that is coupled with music to enhance strength, cardiorespiratory capacity, range of motion, and balance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B-M2M©
Description: The B-M2M© group will receive the same onsite M2M© classes as the Y-M2M© group, but they will also be provided with the option of performing home-based M2M© that will be delivered via videoconferencing.
Study: NCT06449053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ORGANIZATIONAL
Description: A. a formalization of the recommendations to be applied to prevent DILH B. implemented and facilitated by an e-health application C. and will be based on adapting the hospital environment (connected mats, movement sensors, prescription assistance) D. and the dissemination of knowledge (production of summary and empowerment documents).
Study: NCT06456073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E-CEL UVEC cells (AB-207)
Description: Allogeneic (consented-maternal donor) E4ORF1+ (pro-survival gene transduced) human umbilical vein endothelial cells (percutaneous injection formulation)
Study: NCT05111223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real transcranial magnetic stimulation (TMS) before conditioning
Description: Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.
Study: NCT05842798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, intramuscular injection
Study: NCT05111223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real transcranial magnetic stimulation (TMS) before conditioning
Description: Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real transcranial magnetic stimulation (TMS) before devaluation test
Description: Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.
Study: NCT05842798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, intramuscular injection
Study: NCT05111223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real transcranial magnetic stimulation (TMS) before devaluation test
Description: Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial magnetic stimulation (TMS)
Description: Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial magnetic stimulation (TMS)
Description: Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
Study: NCT06239350

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: Research staff will provide skills-based counseling at remote weekly visits, starting at Day 0. Counseling sessions will be brief (\~5-10 minutes) and will focus on strategies for preparing for the quit attempt, dealing with triggers, refusal skills, and enhancing motivation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contingency management
Description: Contingency management (CM): CM will be provided to all study participants to promote abstinence from all nicotine products. Incentives for abstinence (based on submission of a negative cotinine sample) will be provided on an escalating schedule during treatment (Days 8-84).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text-based support
Description: All participants will be provided with evidence-based nicotine cessation resources. For those who are vaping nicotine, participants will be provided information for This is Quitting (SMS text-based program). For those who are primarily smoking cigarettes, NCI's QuitSTART (mobile app, web content), as well SmokefreeTXT (SMS-text based program), will be recommended, potentially in addition to This is Quitting for those using multiple products. These resources provide real time monitoring of nicotine use, mood, triggers and lapses.
Study: NCT06560294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized purified flavonoid fraction (Daflon ®)
Description: Patients will receive micronized purified flavonoid fraction (Daflon ®), 500 mg twice/daily for 3 months.
Study: NCT06380998

Intervention type: DIETARY_SUPPLEMENT
Intervention: whey protien
Description: Whey, the supernatant of yogurt and a byproduct of cheese, is rich in protein and consists of β-lactalbumin, α-lactoglobulin, immunogloblin, bovine serum albumin, and other minor proteins. Whey protein is a globally consumed food material and is well known for its health benefits
Study: NCT06560294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glue embolization
Description: Patients will receive transcatheter glue embolization.
Study: NCT06043037

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elamrousy Novel Approach for Immediate Implant Placement Using Socket Shield Technique
Description: The flapless strategy was used. To prepare the SS, tooth decoronation followed by root splitting mesio-distally. The palatally splitted portion of the root is atraumatically extracted while the intact buccal root portion is kept in place with thickness of 1.5mm.(12) The implant fixture is then placed palatally with 2mm gap distance in between. finally, that gap was grafted with ADDG

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Implant Placement Using Socket Shield Technique alone
Description: The flapless strategy was used. To prepare the SS, tooth decoronation followed by root splitting mesio-distally. The palatally splitted portion of the root is atraumatically extracted while the intact buccal root portion is kept in place with thickness of 1.5mm.(12) The implant fixture is then placed palatally with 2mm gap distance in between. finally, that gap was left without grafts.
Study: NCT05929495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The investigator will identify potential participants and confirm the diagnosis of GBM. Subjects will be screened within 6 weeks before starting treatment.~Treatment will involve:~* Administration of the standard or partial Stupp protocol (Radiotherapy + Temozolomide) in combination with Metformin for 6 weeks,~* Treatment with only Metformin for 4 weeks;~* Resumption of adjuvant TMZ + Metformin treatment continuously until the end of the enrollment period.
Study: NCT05422079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-specific lumbar exercise group
Description: Subjects perform a conventional lumbar exercise program twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor control lumbar exercises
Description: Subjects perform a lumbar stabilization exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor control lumbar exercises with ultrasound echography feedack
Description: Subjects perform a lumbar stabilization exercise program in conjunction with a video where participants can see how the muscles contract.
Study: NCT05014178

Intervention type: DIAGNOSTIC_TEST
Intervention: Sodium-23 MRI
Description: Participants will lay in the MRI bed for approximately 60 minutes during scanning while the MRI technologist takes detailed pictures of their kidneys.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sodium-23 MRI
Description: Participants will lay in the MRI bed for approximately 60 minutes during scanning while the MRI technologist takes detailed pictures of their kidneys.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sodium-23 MRI
Description: Participants will lay in the MRI bed for approximately 60 minutes during scanning while the MRI technologist takes detailed pictures of their kidneys.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sodium-23 MRI
Description: Participants will lay in the MRI bed for approximately 60 minutes during scanning while the MRI technologist takes detailed pictures of their kidneys.
Study: NCT05671965

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol
Description: 33.5g xylitol dissolved in 300mL tap water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 33.5g sucrose dissolved in 300mL tap water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acesulfame Potassium
Description: 0.1675g Ace-K dissolved in 300mL tap water.
Study: NCT05014178

Intervention type: DIAGNOSTIC_TEST
Intervention: Sodium-23 MRI
Description: Participants will lay in the MRI bed for approximately 60 minutes during scanning while the MRI technologist takes detailed pictures of their kidneys.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sodium-23 MRI
Description: Participants will lay in the MRI bed for approximately 60 minutes during scanning while the MRI technologist takes detailed pictures of their kidneys.
Study: NCT05483127

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A toric soft contact lenses
Description: Soft contact lenses for optical correction of ametropia and astigmatism
Study: NCT05818787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Perceptual Learning
Description: The participants will be tilted and asked to indicate their perceived direction of self-motion (e.g., left or right). Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject response, and thus vestibular (i.e., self-motion) perception is required to judge the direction of the tilt stimulus. After each trial, a 3 second period of rest will be given. Each day of training will include three blocks of one-hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Noise cancelling earpieces (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Perceptual Learning
Description: The participants will be tilted and asked to indicate their perceived direction of self-motion (e.g., left or right). Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject response, and thus vestibular (i.e., self-motion) perception is required to judge the direction of the tilt stimulus. After each trial, a 3 second period of rest will be given. Each day of training will include three blocks of one-hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Noise cancelling earpieces (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
Study: NCT05483127

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A toric soft contact lenses
Description: Soft contact lenses for optical correction of ametropia and astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A toric soft contact lenses
Description: Soft contact lenses for optical correction of ametropia and astigmatism
Study: NCT05671965

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 300mL tap water.
Study: NCT06346483

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dusting without Moses 2.0 Modulation
Description: Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
Study: NCT05483127

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A toric soft contact lenses
Description: Soft contact lenses for optical correction of ametropia and astigmatism